ConcertAI’s TeraRecon Surpasses 2,000 Global Customers, Accelerating Cloud-First SaaS Transformation to Further Unlock Productivity for Healthcare Providers

Advanced visualization leader achieves milestone driven by adoption of AI-enabled workflows, partnerships with other industry leaders and country-specific strategies

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ConcertAI’s TeraRecon, a leading provider of AI-empowered AV clinical workflows, visualization ​and interoperability solutions, today announced it has surpassed 2,000 global customers. This milestone reflects the continued acceleration of the company’s cloud-first SaaS transformation with an enterprise-level solution used across clinical imaging domains such as vascular surgery, interventional radiology and cardiology, as well as its success of targeted international expansion strategies designed to meet the complex requirements of diverse healthcare markets.

TeraRecon’s SaaS model eliminates the need for on-premise infrastructure while enabling consistent and scalable access to AI-enabled visualization across institutions ranging from community-based imaging centers to enterprise health systems. The company’s cloud-first approach supports modern healthcare organizations in seeking to unify strategies across their imaging enterprise, while also providing subscription-based access models for smaller providers that aim to reduce IT overhead.

“Our transformation to a cloud-first SaaS model represents a fundamental evolution in how healthcare providers globally can operationalize advanced imaging and AI workflows to unlock productivity and ultimately provide more access for patients,” said Dhiraj Carumbaya, senior vice president and general manager of ConcertAI’s TeraRecon business. “By offering managed services that remove the costly burden of infrastructure and maintenance of on-premise systems, we are enabling providers to standardize imaging workflows, accelerate clinical decision-making and drive efficiency and cost-reductions across a wide range of care settings.”

Targeted International Expansion

Customer growth has also been driven by TeraRecon’s refined commercial model, which prioritizes country-specific market execution over broad regional approaches. Dedicated strategies in the United Kingdom, Germany, Italy and Japan encompass market sizing, key opinion leader engagement and localized demand generation. Core to this expansion has been a focus on meeting the unique compliance and regulatory requirements of each country and province, while still providing the advantages of the cloud.

Strengthening Strategic Partnerships

The shift to SaaS has enabled deeper collaborations with medical image post-processing provider 3DR and global medical device manufacturers, including vascular implants such as stents or structural heart devices, using its cloud services. TeraRecon’s cloud-based advanced visualization and 3D measurement for device sizing, surgical planning and global deployment through managed service agreements reduce the need for partners to maintain their own infrastructure and accelerate access to new markets.

Positioned for Industry Momentum

The milestone aligns with broader healthcare trends, including accelerating adoption of cloud-based clinical applications—now embraced by more than 65% of healthcare organizations worldwide. The advanced visualization market is expanding with a compound annual growth rate (CAGR) of 11.3% over the next five years. At the same time, regulatory bodies have approved over 1,200 AI-enabled algorithms for medical imaging, underscoring the role of AI integration as a key enabler of modern imaging workflows.

“This milestone not only reflects significant global customer adoption, but also validates our strategy of aligning SaaS-based visualization and AI integration with healthcare’s digital transformation imperatives,” Carumbaya added. “As we continue to expand internationally and enhance the scope of our AI-enabled cloud platform, we are well-positioned to meet growing demand for scalable, intelligent imaging solutions worldwide.”

About ConcertAI

ConcertAI is the leader in predictive and generative Al SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers and medical societies. TeraRecon provides AV, AI and image viewing solutions for medical imaging, including 3D post-processing tools used in radiology, cardiology, neurology and oncology. CancerlinQ® is an initiative of ConcertAI, providing oncology providers with ASCO­aligned automated QOPI and ASCO Certified® quality solutions and SmartlinQ™ analytic services. Headquartered in Cambridge, Mass., ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham and Tokyo. For more information, visit us at concertai.com.